Supernus Pharmaceuticals Goodwill and Intangible Assets 2011-2024 | SUPN
Supernus Pharmaceuticals goodwill and intangible assets from 2011 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Supernus Pharmaceuticals Annual Goodwill and Intangible Assets
(Millions of US $) |
| 2023 |
$717 |
| 2022 |
$819 |
| 2021 |
$902 |
| 2020 |
$442 |
| 2019 |
$25 |
| 2018 |
$31 |
| 2017 |
$36 |
| 2016 |
$36 |
| 2015 |
$1 |
| 2014 |
$0 |
| 2013 |
$1 |
| 2012 |
$1 |
| 2011 |
$1 |
| 2010 |
$0 |
Supernus Pharmaceuticals Quarterly Goodwill and Intangible Assets
(Millions of US $) |
| 2024-09-30 |
$657 |
| 2024-06-30 |
$677 |
| 2024-03-31 |
$697 |
| 2023-12-31 |
$717 |
| 2023-09-30 |
$758 |
| 2023-06-30 |
$779 |
| 2023-03-31 |
$800 |
| 2022-12-31 |
$819 |
| 2022-09-30 |
$840 |
| 2022-06-30 |
$859 |
| 2022-03-31 |
$879 |
| 2021-12-31 |
$902 |
| 2021-09-30 |
$425 |
| 2021-06-30 |
$431 |
| 2021-03-31 |
$437 |
| 2020-12-31 |
$442 |
| 2020-09-30 |
$491 |
| 2020-06-30 |
$496 |
| 2020-03-31 |
$24 |
| 2019-12-31 |
$25 |
| 2019-09-30 |
$26 |
| 2019-06-30 |
$29 |
| 2019-03-31 |
$30 |
| 2018-12-31 |
$31 |
| 2018-09-30 |
$33 |
| 2018-06-30 |
$34 |
| 2018-03-31 |
$35 |
| 2017-12-31 |
$36 |
| 2017-09-30 |
$37 |
| 2017-06-30 |
$29 |
| 2017-03-31 |
$29 |
| 2016-12-31 |
$36 |
| 2016-09-30 |
$16 |
| 2016-06-30 |
$16 |
| 2016-03-31 |
$16 |
| 2015-12-31 |
$1 |
| 2015-09-30 |
$17 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$4 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$2 |
| 2013-12-31 |
$1 |
| 2013-09-30 |
$1 |
| 2013-06-30 |
$1 |
| 2013-03-31 |
$1 |
| 2012-12-31 |
$1 |
| 2012-09-30 |
$1 |
| 2012-06-30 |
$1 |
| 2012-03-31 |
$1 |
| 2011-12-31 |
$1 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$0 |
| 2011-03-31 |
$0 |
| 2010-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.978B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
